517 related articles for article (PubMed ID: 24756807)
21. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
22. Vismodegib for Basal Cell Carcinoma and Beyond: What Dermatologists Need to Know.
Alkeraye SS; Alhammad GA; Binkhonain FK
Cutis; 2022 Sep; 110(3):155-158. PubMed ID: 36446122
[TBL] [Abstract][Full Text] [Related]
23. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
25. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
27. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
28. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
29. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
30. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
Sekulic A; Migden MR; Oro AE; Dirix L; Lewis KD; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Low JA; Mackey HM; Yauch RL; Graham RA; Reddy JC; Hauschild A
N Engl J Med; 2012 Jun; 366(23):2171-9. PubMed ID: 22670903
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
33. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
35. Vismodegib in basal cell carcinoma.
Amaria RN; Bowles DW; Lewis KD; Jimeno A
Drugs Today (Barc); 2012 Jul; 48(7):459-67. PubMed ID: 22844657
[TBL] [Abstract][Full Text] [Related]
36. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
37. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
38. [Vismodegib in metastasized basal cell carcinoma].
Reinders MG; Dirix L; Mosterd K; van Doorn R
Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
[TBL] [Abstract][Full Text] [Related]
39. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
Keating GM
Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]